33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
    Meeting Abstract

    Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance])
    Meeting Abstract

    Cheng, E.; Qian, S.; Shields, A. F.; Cespedes Feliciano, E. M.; Nixon, A. B.; Shergill, A. P.; Guthrie, K. A.; Couture, F.; Kuebler, P.; Kumar, P.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
    Meeting Abstract

    Lonial, S.; Richard, S.; Matous, J. V.; Yee, A. J.; Shah, U.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Ailawadhi, S.; Richardson, P. G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer
    Meeting Abstract

    Ravi, A.; Gainor, J.; Arniella, M.; Stewart, C.; Freeman, S.; Awad, M. M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J. W.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Exploring the impact of infertility and its treatments on risk of ovarian cancer
    Meeting Abstract

    Lee, A. W.; Phung, M. T.; Jensen, A.; Wu, A. H.; Cramer, D. W.; Modugno, F.; Harris, H.; Doherty, J. A.; Schildkraut, J.; Terry, K. L.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
    Meeting Abstract

    Gounder, M. M.; Schwartz, G. K.; Jones, R. L.; Chawla, S. P.; Chua-Alcala, V. S.; Stacchiotti, S.; Wagner, A. J.; Cote, G. M.; Maki, R. G.; Kosela-Paterczyk, H.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100
    Meeting Abstract

    Dy, G. K.; Govindan, R.; Velcheti, V.; Falchook, G. S.; Italiano, A.; Wolf, J.; Sacher, A. G.; Takahashi, T.; Ramalingam, S. S.; Dooms, C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial
    Meeting Abstract

    Jäger, U.; Han, X.; Germano, D.; Quinn, D.; Gaddis, D.; Masood, A.; Mulvey, T.; Mataraza, J.; Bishop, M. R.; Salles, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
    Meeting Abstract

    Naing, A.; Callahan, M.; Costello, B. A.; Curti, B.; Hall, E.; Hansen, A.; Long, G. V.; Joshua, A. M.; Wetmore, C.; Weickhardt, A.
    Cancer Research (2022)

    Fulltext@MSK | Save